Objectives: To determine the maximum tolerable doses (MTDs) of irinotecan (CPT-11) and 5-fluorouracil (5-FU) plus levofolinic acid (LFA) administered together every two weeks, to define the toxicity profile of this regimen, and to have a preliminary evidence of its activity in the first-line management of advanced colorectal cancer patients.
Introduction
Colorectal carcinoma is one of the most chemo-resistant tumours. Over the past 40 years, 5-fluorouracil (5-FU) has been the most extensively used drug, and is still considered a mainstay in the treatment of this disease, although it produces major response in only about 10% of patients [1] . In the past decade, the addition of other cytotoxic drugs to 5-FU has not yielded results better than those of 5-FU alone in comparative trials. Therefore, several efforts have recently been made in the field of biochemical modulation of 5-FU, in an attempt to increase its activity and/or reduce its toxicity by the addition of other compounds that might interfere with its metabolic pathway.
Folinic acid (FA) has been proven to modulate 5-FU activity. Indeed, representing a source of N ,N 10 -methylenetetrahydrofolate (N 5 ,N 10 -CH 2 FH 4 ), it may optimise the inhibition of thymidylate synthase (TS) by increasing the formation of a stabilised ternary complex between TS, 5-fluorodeoxyuridine monophosphate and N 5 ,N l0 -CH 2 FH4. Randomised phase III studies comparing 5-FU plus FA to 5-FU alone have been carried out around the world, and a meta-analysis of nine of these trials highlighted the significant overall advantage of the combination in terms of response rate (23% vs. 11%), but only a minor impact on survival [2] .
More recently, newer compounds (raltitrexed, irinotecan, and oxaliplatin) have shown activity in colorectal cancer comparable to modulated-5-FU. Irinotecan (CPT-11) is an inhibitor of topoisomerase I (Topo-I), an enzyme responsible for variations in the topological form of DNA during replication and transcription. Topo-I levels were found to be more than ten-fold higher in cancerous tissue than in normal colonic mucosa [3] . The cytotoxic effect of CPT-11, and especially of its principal active metabolite SN-38, is specific for the S-phase of the cell cycle. As second-line treatment in patients refractory to 5-FU, CPT-11 has shown a consistent activity, demonstrating a lack of cross-resistance with 5-FU [6, 7] . However, there is no complete agreement on the dosage and schedule of CPT-11 to be used. In Japan, and later in the USA, a weekly schedule has been utilised, with dosage ranging from 100 to 150 mg/m 2 [8] [9] [10] . More recently, a fortnightly administration of 250 mg/m 2 was tested which yielded a response rate comparable to that of the previous schedules [11] . In Europe, a three-weekly schedule with a higher dosage (350 mg/m 2 ) has usually been used [12] . This is also the schedule tested in two randomised trials comparing CPT-11 to either supportive therapy alone or to infusional 5-FU in patients with advanced colorectal carcinoma refractory to previous treatment. In both studies, patients receiving the experimental treatment gained a benefit in survival and symptom control over those of the control patients [13, 14] .
The preclinical synergistic inhibition of growth shown by CPT-11 and 5-FU on cultured colon carcinoma cell lines, and the demonstrated activity of CPT-11 in patients with advanced colorectal carcinoma clearly refractory to previous 5-FU treatment, are the rationale for combining CPT-11 and 5-FU in the front-line management of these patients. A number of studies are underway or have recently been concluded, testing different dosages and schedules of the two drugs. Also in this case, different approaches were used in the USA and Europe. In the USA, CPT-11 was combined with i.v. bolus 5-FU+FA in the daily-times-five monthly or oncea-week regimens that represent the standard treatments in that country [15, 16] while in Europe CPT-11 has been combined with a variety of regimens of infusional 5-FU ± FA, differing in duration and schedule [17] [18] [19] [20] [21] [22] .
Theoretically, the cytotoxic activity of phase-specific anti-proliferate drugs such as CPT-11 and 5-FU should be better exploited with frequent administrations, thereby increasing the likelihood that tumour cells will be exposed to these drugs while in S-phase. From the practical viewpoint, a biweekly administration of both drugs (24-hour apart) as i.v. bolus or short infusion seems a good compromise between the weekly and every-threeweek schedules, at least with respect to compliance of both patient and physician, with an easily handled outpatient therapy. We have already experienced such a schedule for the double modulation of 5-FU by previous exposure to MTX and levo-folinic acid (LEA) in gastrointestinal diseases [23] and have decided to stay with this schedule in the present study to define the maximum tolerable dose of CPT-11 and 5-FU given in combination with a fixed dose of LEA.
Patients and methods

Patients selection
Patients were required to have histologically proven diagnoses of locally advanced or metastatic colorectal carcinoma. Other eligibility criteria were: age from 18 to 75 years; performance status < 2 of the Eastern Cooperative Oncology Group (ECOG) scale; presence of measurable or evaluable indicator lesion(s); no previous chemotherapy for the advanced disease (adjuvant chemotherapy was allowed provided that it had been discontinued for at least six months); white blood cell count ^3500/mmc and neutrophil count (ANC) >2000/mmc, platelet (PLT) count > 100,000/mmc, haemoglobin (Hb) level > 10 g/dl; bilirubin <1.25x upper normal limit (UNL), ALT and AST ^ 2.5 x UNL in absence of liver metastases, or bilirubin < 1.5 x UNL, ALT and AST ^ 5 x UNL in presence of liver metastases; normal renal function (creatinine clearance < 60 ml/min). Exclusion criteria were: inflammatory bowel diseases or significant diarrhoea in recent weeks (or during prior adjuvant 5-FU administration); total colectomy or ileostomy; bowel obstruction; uncontrolled metabolic disorders or active infections; severe ischaemic disease or acute myocardial infarction in the last six months. All eligible patients gave their informed consent for participation in this study which had been approved by the Ethics Committee for Biological Research of the National Tumour Institute of Naples, and carried out according to the Good Clinical Practice guidelines.
Diagnostic procedures
At study entry, all patients were submitted to physical examination with evaluation of the performance status score; complete blood cell counts and biochemistry; dosage of carcinoembryonic antigen serum level (CEA), and CA 19.9; cardiologic evaluation with ECG; chest X-ray and computed tomographic (CT) scan of the abdomen and pelvis. The indicator lesion(s) were measured with CTscan or magnetic nuclear resonance (MNR) imaging.
To detect acute haematological toxicity, blood cell count with differential was performed weekly, and biochemistry every other week. Extra-haematological acute toxicity of each cycle was assessed at the time of recycling. All acute side effects were scored according to the WHO Classification. Both the toxicity reported in all cycles and the worst side effects experienced by each patient during his/her treatment were recorded.
Study design
The main aim of this study was to determine the maximum tolerable doses (MTDs) of both CPT-11 and 5-FU given with a fixed dose of LEA 250 mg/m 2 every 2 weeks. Patients received CPT-11 on day 1 given as one-hour i.v. infusion, followed on day 2 by 5-FU as i.v. bolus (in 2-5 min) at the end of LFA two-hour i.v. infusion. Anti-HT3 receptors were routinely administered before CPT-11 on day 1 to prevent vomiting. Atropine premedication was not performed for the first cycle, but was allowed for subsequent cycles as prophylaxis of the cholinergic syndrome. Furthermore, patients received appropriate information about how to manage delayed diarrhoea at home with an intensive loperamide assumption every two hours for a maximum of 48 hours.
The starting doses of CPT-11 and 5-FU were 150 mg/m 2 and Table I . Main characteristics of enrolled patients. 600 mg/m 2 , respectively. At least three patients were treated with each dose level. If dose limiting toxicity (DLT) was observed in one of three patients, three further patients had to be treated with the same doses. If 2 of 3 or > 4 of 6 patients experienced the same DLT, the dose escalation had to be stopped. Otherwise, dosages of both CPT-11 and 5-FU were alternately escalated.
Characteristics
The DLTs were defined as: 1) WHO grade 4 neutropenia or thrombocytopenia; 2) WHO grade 3 neutropenia with fever >38°C lasting more than 24 hours; 3) WHO grade 3 thrombocytopenia with bleeding; 4) any WHO grades 3 or 4 extra-haematological toxicity (except alopecia or vomiting); 5) a delay > 2 weeks in recycling. The last tested level of dose escalation had to be considered as the MTD, and the dose level immediately below should be recommended for further evaluation.
Duration of treatment
No intrapatient dose escalation was allowed. Thus, patients were treated with the same dose level until a major response was achieved, or progressive disease was documented. Treatment was interrupted earlier only in cases of unacceptable toxicity or patient refusal. Courses were administered every other week, provided that ANC > 1500/mmc and PLT > 100,000/mmc; otherwise, a 1-2-week delay was allowed to obtain complete bone marrow recovery. Doses of both CPT-11 and 5-FU had to be reduced to 75% of the initial ones in case of incomplete bone marrow recovery on day 29, or after the complete recovery from WHO grade 4 neutropenia or grade 3 diarrhoea in previous cycle. 
Response assessment
Response to treatment was assessed every four courses by repeating all initially abnormal diagnostic tests. Response was graded according to WHO criteria [24] in complete response (CR), partial response (PR), no change (NC) or progressive disease. Duration of response was calculated from the time it was firstly documented (CR) or from the start of therapy (PR). Time to treatment failure was calculated from the date of initial therapy to its discontinuation because of any cause (progressive disease, toxicity, and refusal). Survival was calculated from the start of treatment to the patient's death from any cause, or to last follow-up.
Statistics
Haematological toxicity was assessed for the first cycle of each patient enrolled at each dose level. Percent of patients at each dose level suffering from grades 3 and 4 haematological and non-haematological toxicity during their entire treatment was also evaluated.
To verify the feasibility of multiple cycles, the actually delivered dose intensity of both cytotoxic drugs during the first four (DI 4 ), and eight (DI 8 ) cycles of treatment was calculated.
Exact 95% confidence intervals (95% CI) of response rate were derived from binomial distribution. Duration of response and survival was estimated by the Kaplan-Meier method.
Results
Patients
From 10 July 1997 to 20 August 1998, 31 patients were entered into this study. The main patient characteristics are listed in Table 1 . All patients met the eligibility criteria. It is worth noting that only five (16%) patients had received 5-FU-based adjuvant chemotherapy.
Dose escalation results
A total of six dose levels were tested, as reported in Table 2 . At the first two dose levels, combining CPT-11, 150 mg/m 2 , with 5-FU at either 600 or 750 mg/m 2 , no DLTs were observed. At the subsequent escalation of CPT-11 dosage to 175 mg/m 2 , three of six patients showed a transient grade 4 neutropenia after the first course, while the next increment of 5-FU dose to 950 mg/m 2 caused a severe diarrhoea in two of six patients. The last increase in the CPT-11 dose to 210 mg/m 2 produced a grade 4 neutropenia in four patients, associated in one of them with grade 3 stomatitis. Therefore, this dose level was considered the MTD. However, before considering the previous dose level as the one to be recommended for phase II study, we tried a further step, slightly decreasing the 5-FU dose from 950 to 850 mg/m 2 and the CPT-11 dose from 210 to 200 mg/m 2 . At this dose level, seven patients were enrolled, and six were properly evaluated for toxicity after the first cycle. Two of these patients showed a DLT consisting of diarrhoea in one case, and neutropenia in the other. In summary, grade 4 neutropenia was the main acute toxicity, representing 8 of 11 episodes of DLTs encountered during the dose escalation of this study.
Cumulative acute toxicity
A total of 293 courses were administered, with a median number of 8 (range 1-19) cycles per patient. No toxic deaths occurred in this trial. The worst acute haematological toxicity reported by each patient during treatment is reported in Table 3 .
Neutropenia was the haematological side effect most frequently observed during treatment, occurring in 28 of 31 (90%) treated patients, and reaching grades 3 and 4 in 6 (19%) and 13 (42%) of patients, respectively. Severe neutropenia resulted in direct relation to the dosages utilised. Indeed, grade 3-4 neutropenia occurred during treatment in one of three patients of first two levels, in three of six patients of the third level, in four of six patients of the fourth level, in six of six patients of the fifth level. However, at the last level, decreasing both CPT-11 and 5-FU doses, severe neutropenia occurred in four of seven patients. In any case, the neutropenia was usually of short duration. Two patients suffered from an episode of severe infection, but in only one case was it associated with grade 4 neutropenia. Anaemia was registered in 15 (48%) patients, but was usually mild, being of grade 3 in 1 case. Thrombocytopenia was negligible, with grade 1 reported in only two patients.
The main non-haematological toxicity is listed in Table 4 . Some grade of nausea or vomiting affected 21 of 31 (68%) patients despite the prophylactic use of anti-HT3 receptors, but additional anti-emetic treatment usually limited the severity of gastric disturbance in the majority of them. Diarrhoea was frequently complained of by patients (61%), but it was not a major problem, since it was of grade 3 or 4 in only two (13%) patients. It is interesting to note that at the last dose level the occurrence of severe diarrhoea was about one-half that reported with the fourth dose level. Stomatitis seldom occurred (16% of patients), but when it did was usually mild. Partial or complete hair loss during treatment was observed in 7 and 16 patients, respectively. Acute cholinergic-like syndrome (diaphoresis, hyperlacrimation, rhinorrhoea, abdominal cramps) affected four patients soon after their first i.v. infusion of CPT-11. The occurrence and severity of this syndrome seemed unrelated to CPT-11 dose, since it was reported at different dose levels tested. In any case, it was rapidly controlled, and subsequently prevented, by SC administration of 0.25-0.50 mg of atropine sulphate. As previously mentioned, two patients suffered from severe episodes of sepsis. In one case it was due to central vein catheter infection requiring its removal. The other patient had a neutropenic fever that was controlled by systemic antibiotic and G-CSF support. Two patients complained of some asthenia during their treatment, probably related to a concomitant occurrence of mild/moderate anaemia.
Delivered dose intensity
Since two dose levels, i.e., CPT-11 175 mg/m 2 combined with 5-FU 950 mg/m 2 , and CPT-11 200 mg/m 2 combined with 5-FU 850 mg/m 2 , were safe and suitable for further evaluation, we analysed the actually delivered cumulative doses and dose intensities of both cytotoxic drugs over the first four (DI 4 ) and eight (DI 8 ) courses of treatment received by each patient treated at these two dose levels. At the fourth dose level, CPT-11 median delivered DI 4 was 64 (range 61-88) and DI 8 
Response and survival
Although anti-tumour response was not the primary parameter under study, a summary of responses observed is reported in Table 5 . Five patients were not assessed for response: one patient received less than four courses because of rapid deterioration of his clinical condition; in two other patients the treatment was discontinued early because of prolonged myelosuppression, or occurrence of severe diarrhoea despite dose reduction (one case each); two more patients discontinued their treatment after the first cycle: one patient experienced a grade 4 diarrhoea and refused further chemotherapy at reduced doses, while the other was referred to another centre for logistical reasons. A total of 14 major responses (3 CRs and 11 PRs) were reported among 26 evaluated patients, yielding a 54% (95% CI: 33%-73%) response rate according to standard analysis, or a 45% (95% CI: 27%-64%) response rate according to an intent-to-treat analysis. Of note, four PRs were registered in patients that had already received 5-FUmodulated adjuvant chemotherapy. Responses were documented after a median of 11 (range 8-26) weeks of treatment, and their length ranged between 10+ and 43+ weeks. All three CR patients were still without recurrence of disease 10+, 31+, and 41+ weeks after their response was initially documented.
The median potential follow-up of all patients, as of 31 December 1998, was 39 weeks, ranging from 17 to 78 weeks. At the time of this analysis, 15 patients had shown treatment failure, and 10 of them had died. The median failure-free and overall survivals at the time of this analysis were 42 and 55 weeks, respectively.
Discussion
Among the new recently available cytotoxic compounds, CPT-11 is the most extensively studied in the second-line treatment of advanced colorectal carcinoma, and in large phase II studies it has been demonstrated to possess consistent activity in patients resistant to previous 5-FU-based chemotherapy. Indeed, in a pooled analysis of four phase II studies, the mean overall response rate was 13% (range 10%-17%) among 363 treated patients [6, 7, 12] . In two randomised trials conducted in 5-FUrefractory patients, CPT-11 was compared to either an infusional 5-FU regimen [13] , or to best supportive care alone [14] , and it induced a survival improvement and a clinical benefit for treated patients in both trials. These findings demonstrate that CPT-11 is an active drug against colorectal carcinoma, and confirm the preclinical observations about the absence of cross-resistance between CPT-11 and 5-FU. Therefore, there is a strong rationale for combining them in the front-line treatment of patients with advanced disease.
However, as already mentioned, there is no general agreement about the best schedule of administration of CPT-11. While in the European trials CPT-11 was given at 350 mg/m 2 every three weeks [6, [12] [13] [14] , in Japan and thereafter in USA a different schedule has been developed, administering 100-125 mg/m 2 once weekly for four weeks followed by a two-week rest period [9, 10] . These two schedules have shown no relevant differences in activity or toxicity profile. More recently, a new schedule of 250 mg/m 2 every other week has been tested in colorectal cancer patients. A 13% overall response rate has been reported among 92 pretreated patients, with no substantial increase of neutropenia or delayed diarrhoea [10] .
Since CPT-11 and 5-FU are cell cycle-specific drugs, a more frequent administration of these drugs seems advisable because it should increase the likelihood that any given tumour cell will be exposed to cytotoxic concentration of either SN-38 (the active metabolite of CPT-11) and 5-FU while in S-phase. Furthermore, the synergism demonstrated in preclinical studies between CPT-11 and 5-FU is in favour of the concomitant rather than alternated administration of these two drugs. Finally, it was demonstrated in preclinical studies that this synergism was strictly schedule-dependent, being maximally exploited when CPT-11 preceded 5-FU [26] .
For these reasons, we decided to give irinotecan on the day before the modulated 5-FU i.v. bolus administration, and we have chosen a fortnightly schedule as a mid-point between the weekly and the every-three-week schedule because it is easy to administer as outpatient treatment.
As for the toxicity of our schedule, we would point out the good tolerabiiity shown by the last cohort of our patients. Namely, the occurrence of severe neutropenia and diarrhoea was similar to that reported when the two cytotoxic drugs were given in alternated sequence [14] . This finding may be a consequence of the different mechanisms of action and/or pharmacokinetic behaviour of the two cytotoxic drugs. Indeed, when 5-FU is administered as i.v. bolus, its half-life is largely dependent on the DPD activity in the liver, while other sites, such as lung or kidney, may contribute to its catabolism when it is administered as continuous infusion. It should be remembered that with 5-FU i.v. bolus the liver clearance may be saturated, leading to a non-linear relationship between 5-FU dose and its plasma level. That means that 5-FU plasma concentration rose much more steeply than expected on the basis of a linear pharmacokinetics, and a moderate dosage increment may cause unpredictable acute toxicity, while a slight decrease may render the drug far better tolerated than expected.
Conversely, the area under the concentration versus time curves (AUC) of CPT-11 increases linearly with the dosage administered. At 200 mg/m 2 , the corresponding average AUC is 20 ug • h/ml, while with 350 mg/m 2 the average AUC raises to 30 ugh/ml. The analysis of correlation between CPT-11 exposure and its induced myelotoxicity showed that a less than 50% decrease of initial ANC was associated with a CPT-11 AUC of 20.6, while a decrease between 50% and 75%, or more than 75% of initial ANC values, was associated with CPT-11 AUC of 34.3 or 42.4, respectively. Similarly, a less than WHO grade 2 diarrhoea was associated with a CPT-11 AUC of 18.1, while a grade 2+ diarrhoea was associated with CPT-11 AUC ^ 30 [4, 5] .
On the other hand, above a threshold dose, a clear correlation between increasing dose of CPT-11 and its activity was not apparent in initial studies [5] , nor in recent trials. As already mentioned, a similar response rate (about 13%) was reported in 5-FU-refractory patients, regardless of dosage and schedule of CPT-11 employed [6] [7] [8] [9] . More recently, a 36% overall activity in unpretreated patients was obtained with a higher than usual dosage (500 mg/m 2 every three weeks) of CPT-11 [29] ; this result does not appear substantially different from the 32% response rate reported by Conti et at. [10] with 125 mg/m 2 weekly for four of six weeks. In our study, responses were obtained from the first dose level tested, suggesting that the scheduling of the drugs more than their dosage was the major determinant of activity of this regimen. Moreover, the dose escalation of 5-FU augmented the risk of mucositis (diarrhoea or stomatitis), without a significantly increased activity.
In conclusion, we believe that the biweekly administration of CPT-11 and 5-FU + LFA at the recommended doses of this study is a convenient, moderately toxic, and very active regimen for the treatment of patients with advanced colorectal carcinoma. A phase II multicenter study is already underway to more precisely assess its activity and toxicity.
